Fig. 5From: Patterns of pseudoprogression across different cancer entities treated with immune checkpoint inhibitorsTumor response following pseudoprogression. NSCLC Non-small cell lung cancer, RCC renal cell carcinoma, HCC hepatocellular carcinoma, ENT ear nose throat carcinoma, CUP carcinoma of unknown primary, CRC colorectal carcinoma, CCC cholangiocellular carcinoma, PDAC pancreatic ductal adenocarcinoma, SLCL small cell lung cancer, UCC urothelium cell carcinomaBack to article page